GLP-1 drugs are reshaping weight loss — and changing the way people eat. But for a lot of people, the experience comes with multiple tradeoffs. The conversation is shifting — from “How do I lose weight?” to “How do I maintain my new body weight?”
You can already see early signals. Even public figures like Oprah are talking openly about their GLP-1 journey and the challenge of “beating the rebound.”
We think that in the next 12 months, the post-GLP-1 period will become one of the biggest opportunities in consumer health — and Metabolize is being built specifically for this moment.
This interview took place in January 2026 with Metabolize CEO & Co-Founder Morris Laster, MD.
What are Metabolize’s products?
Our lead products, NatLean and MetaPair, are built on two key pillars.
The first pillar is to act through non-GLP-1 mechanisms to support weight maintenance and reduce rebound risk.
The second pillar is to support maintaining lean muscle mass, which is one of the best predictors of maintaining metabolic health — especially during rapid weight change.
Our launch product, NatLean, is designed specifically for people cycling off of GLP-1’s. It’s intended to support weight maintenance, be muscle-sparing, and improve key metabolic markers such as hemoglobin A1C.
Our second product, MetaPair, is a GLP-1 alternative for people who are GLP-1 ineligible or intolerant. It is designed to help people lose weight without any harsh side effects or muscle loss
Why are so many people on GLP1 cycling off the drug?
There is a range of issues causing those on GLP1 to cycle off the drug, they include GI distress directly due to the drug’s mechanism of action, significant muscle and bone loss, and the high cost of the medication.
Our supplements work via a novel non-GLP1 mechanism, which allows our customers to sidestep many of these issues, letting weight management be more under their control.
Aren’t the costs of GLP1s coming down dramatically, so they’ll be affordable for chronic long term care?
Yes, political and payer pressures will lower their prices. But the side effects are significant and are significant enough that the vast majority of people will be on them for 6 months to 2 years. Longer term, people using GLP1s need solutions like Metabolize.
How was Stanford involved in Metabolize?
The deep science behind our products is actually our core differentiator.
Metabolize is translating decades of metabolism and nutrition research from Dr. Jonathan Long’s lab at Stanford into products designed for real-world use. We have an exclusive license to that Stanford IP.
Based on recent animal studies, NatLean promises to virtually prevent the post GLP1 rebound. Further, we saw no reduction in muscle strength and close to 30% reductions in key metabolic markers such as glucose, triglycerides, and cholesterol.
Most supplements do not have decades of science or proof-of-concept animal data supporting their mechanism. But we do. We will be the first non-GLP1 supplement to truly help people beat the rebound.
How soon will you be on the market?
We’re launching our first GLP-1 off-ramp product, NATlean, in the next few months. Our waitlist is building every day. Our second-generation product will launch at the end of 2026.
Our molecules also have properties that make them ideal for formulating into everyday food and drinks. So we’re talking to brands, big and small, about licensing deals to create whole new product lines of metabolically friendly foods.
There is a huge opportunity in nutrition and supplements here, and we at Metabolize are excited to lead the way in setting a new evidence-based paradigm for the post-GLP1 era.
